海南医学
海南醫學
해남의학
HAINAN MEDICAL JOURNAL
2015年
12期
1722-1724
,共3页
夏翠锋%李强%沈焘%程先硕%李云峰
夏翠鋒%李彊%瀋燾%程先碩%李雲峰
하취봉%리강%침도%정선석%리운봉
血管内皮生长因子%癌胚抗原%内皮抑素%大肠癌%肝转移
血管內皮生長因子%癌胚抗原%內皮抑素%大腸癌%肝轉移
혈관내피생장인자%암배항원%내피억소%대장암%간전이
Vascular endothelial growth factor (VEGF)%Carcinoembryonic antigen (CEA)%Endostatin%Colorectal cancer%Hepatic metastasis
目的:探讨血管内皮生长因子(VEGF)、癌胚抗原(CEA)、内皮抑素(Endostatin)在不同分期大肠癌中的表达及其与肝转移的关系。方法选取我院大肠癌手术患者116例,术中采集大肠癌组织(癌症组,116例)和癌旁正常大肠组织(正常组,100例),采用免疫组织化学方法检测VEGF、CEA、Endostatin表达情况,比较三者在不同临床分期大肠癌中的表达及其与肝转移的相关性。结果癌症组VEGF、CEA阳性率明显高于正常组,Ⅲ~Ⅳ期大肠癌组织VEGF、CEA阳性率明显高于Ⅰ~Ⅱ期,比较差异均具有统计学意义(P<0.05);癌症组Endostatin阳性率明显低于正常组,Ⅲ~Ⅳ期大肠癌组织Endostatin阳性率明显低于Ⅰ~Ⅱ期,比较差异均具有统计学意义(P<0.05)。同时性肝转移者VEGF、CEA阳性率明显高于无肝转移者,Endostatin阳性率明显低于异时性肝转移和无肝转移者,异时性肝转移者CEA阳性率明显高于无肝转移者,差异均具有统计学意义(P<0.05)。结论 VEGF、CEA在大肠癌组织中显著高表达,Endostatin在大肠癌组织中显著低表达,其中临床分期越高,合并肝转移,VEGF、CEA阳性率越高,Endostatin阳性率越低,三者表达在评估临床分期、肝转移类型中具有重要价值。
目的:探討血管內皮生長因子(VEGF)、癌胚抗原(CEA)、內皮抑素(Endostatin)在不同分期大腸癌中的錶達及其與肝轉移的關繫。方法選取我院大腸癌手術患者116例,術中採集大腸癌組織(癌癥組,116例)和癌徬正常大腸組織(正常組,100例),採用免疫組織化學方法檢測VEGF、CEA、Endostatin錶達情況,比較三者在不同臨床分期大腸癌中的錶達及其與肝轉移的相關性。結果癌癥組VEGF、CEA暘性率明顯高于正常組,Ⅲ~Ⅳ期大腸癌組織VEGF、CEA暘性率明顯高于Ⅰ~Ⅱ期,比較差異均具有統計學意義(P<0.05);癌癥組Endostatin暘性率明顯低于正常組,Ⅲ~Ⅳ期大腸癌組織Endostatin暘性率明顯低于Ⅰ~Ⅱ期,比較差異均具有統計學意義(P<0.05)。同時性肝轉移者VEGF、CEA暘性率明顯高于無肝轉移者,Endostatin暘性率明顯低于異時性肝轉移和無肝轉移者,異時性肝轉移者CEA暘性率明顯高于無肝轉移者,差異均具有統計學意義(P<0.05)。結論 VEGF、CEA在大腸癌組織中顯著高錶達,Endostatin在大腸癌組織中顯著低錶達,其中臨床分期越高,閤併肝轉移,VEGF、CEA暘性率越高,Endostatin暘性率越低,三者錶達在評估臨床分期、肝轉移類型中具有重要價值。
목적:탐토혈관내피생장인자(VEGF)、암배항원(CEA)、내피억소(Endostatin)재불동분기대장암중적표체급기여간전이적관계。방법선취아원대장암수술환자116례,술중채집대장암조직(암증조,116례)화암방정상대장조직(정상조,100례),채용면역조직화학방법검측VEGF、CEA、Endostatin표체정황,비교삼자재불동림상분기대장암중적표체급기여간전이적상관성。결과암증조VEGF、CEA양성솔명현고우정상조,Ⅲ~Ⅳ기대장암조직VEGF、CEA양성솔명현고우Ⅰ~Ⅱ기,비교차이균구유통계학의의(P<0.05);암증조Endostatin양성솔명현저우정상조,Ⅲ~Ⅳ기대장암조직Endostatin양성솔명현저우Ⅰ~Ⅱ기,비교차이균구유통계학의의(P<0.05)。동시성간전이자VEGF、CEA양성솔명현고우무간전이자,Endostatin양성솔명현저우이시성간전이화무간전이자,이시성간전이자CEA양성솔명현고우무간전이자,차이균구유통계학의의(P<0.05)。결론 VEGF、CEA재대장암조직중현저고표체,Endostatin재대장암조직중현저저표체,기중림상분기월고,합병간전이,VEGF、CEA양성솔월고,Endostatin양성솔월저,삼자표체재평고림상분기、간전이류형중구유중요개치。
Objective To investigate the expression of vascular endothelial growth factor (VEGF), carci-no-embryonic antigen (CEA), Endostatin in different stages of colorectal cancer and their correlations with hepatic me-tastasis. Methods A total of 116 patients of colorectal cancer were selected in our hospital. Samples were collected from colorectal cancer tissues (cancer group, n=116) and the adjacent normal colon tissues (normal group, n=100). The expression of VEGF, CEA, Endostatin were detected by immunohistochemical method, and then compared be-tween different clinical stages. Their correlations with hepatic metastasis were analyzed. Results The positive expres-sion rate of VEGF, CEA were significantly higher in cancer group than normal group, and also inⅢ~Ⅳstage colorec-tal cancer thanⅠ~Ⅱstage colorectal cancer, with statistically significant differences (P<0.05). The positive expres-sion rate of Endostatin were significantly lower in cancer group than normal group, and also inⅢ~Ⅳstage colorectal cancer thanⅠ~Ⅱstage colorectal cancer, with statistically significant differences (P<0.05). The positive expression rate of CEA, VEGF were significantly higher in patients with synchronous hepatic metastasis than those without hepat-ic metastases;the positive expression rate of Endostatin was significantly lower in patients with synchronous hepatic metastasis than those with metachronous hepatic metastasis and those without hepatic metastasis;the positive expres-sion rate of CEA was significantly higher in patients with metachronous hepatic metastasis than those without hepatic metastasis. The differences were all statistically significant (P<0.05). Conclusion VEGF, CEA show significantly in-creased expression in colorectal cancer tissues, and Endostatin has significantly lowered expression in colorectal can-cer tissues. With the development of clinical stage or the complication of hepatic metastasis, the positive expression rates of CEA, VEGF increase and the positive expression rate of Endostatin decreases. The expression of the three in-dexes have important value in evaluating clinical stage and hepatic metastasis.